In this review, we discuss how the genetic hypercalciuric stone-forming (GHS) rats, which closely model idiopathic hypercalciuria and stone formation in humans, provide insights into the pathophysiology and consequences of clinical hypercalciuria.
INTRODUCTION
The majority of patients who form calcium (Ca)containing kidney stones are hypercalciuric as compared with nonstone formers [1] [2] [3] [4] [5] . At least a third of these patients have no demonstrable metabolic cause for the increased urinary (u) Ca excretion and are classified as having idiopathic hypercalciuria (IH). Patients with idiopathic hypercalciuria generally have normal serum (s) Ca, normal or elevated s1,25(OH) 2 D 3 (1,25D), normal or elevated s parathyroid hormone (sPTH), normal or low s phosphate (sP). These patients are often in negative Ca balance, that is they excrete more calcium in their urine than they absorb from their diet, indicating a net loss of total body calcium [1, 3, [6] [7] [8] [9] [10] [11] [12] [13] [14] and they often have a reduction in bone mass [3, 6, [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] and an increase in the rate of fracture [20, 27] . Idiopathic hypercalciuria exhibits a polygenic mode of inheritance [2, 29, 30] .
To study idiopathic hypercalciuria in ways that are impossible in man, we have established a novel rat strain, the genetic hypercalciuric stone-forming (GHS) rat, by inbreeding the most hypercalciuric progeny of successive generations of Sprague-Dawley rats . When fed a standard, ample Ca diet, each GHS rat now consistently excretes $10-fold more uCa than Sprague-Dawley controls . In common with patients with idiopathic hypercalciuria, GHS rats have normal sCa [32] , increased intestinal Ca absorption [38] and enhanced bone resorption [37] , decreased renal tubule Ca reabsorption [39] , and normal s1,25D levels [36, 38, 45, 46, 53] , in addition to decreased bone mineral density (BMD) [35, 40] . Hypercalciuria is a polygenic trait in GHS rats [43] as it is in humans [2, 29, 30] . When fed a standard, ample Ca diet, all GHS rats develop kidney stones [33, 52, 54, 55] which are composed of calcium phosphate (CaP) [33, 49, 50, 54] . Addition of the amino acid hydroxyproline to the diet of GHS rats results in calcium oxalate (CaOx) stone formation [31, 34, 47] . The GHS rats have been maintained with continuous selection for hypercalciuria for over 100 generations ( Fig. 1 ) [31-36,39,40,42,44,47, 49-52,54- 
We have used the GHS rats to address fundamental questions in the pathophysiology of hypercalciuria and Ca stone formation and resultant effects on bone.
WHAT IS THE ORIGIN OF THE INCREASED URINARY CALCIUM IN GENETIC HYPERCALCIURIC STONE-FORMING RATS?
All uCa must originate from intestinal absorption of dietary Ca, and bone Ca is, by far, the largest repository of Ca in the body [26] . An increase in uCa may result from increased intestinal Ca absorption, increased bone resorption or a failure of renal tubular Ca reabsorption, which would then drive increased Ca absorption and resorption to maintain serum Ca.
To determine whether the GHS rats have increased intestinal Ca absorption, we measured Ca transport in isolated duodenum using an Ussing chamber [32] . We found that the mucosal to serosal Ca flux (absorption) in GHS was higher than that in Sprague-Dawley, and there was no difference in the serosal to mucosal flux (secretion) indicating greater net Ca absorption in the GHS compared with Sprague-Dawley rats.
That there is an increase in intestinal Ca absorption in the GHS rats does not preclude that enhanced bone resorption or a defect in renal tubular Ca reabsorption contributes to the hypercalciuria. Using a low Ca diet (LCD) to effectively eliminate dietary Ca absorption, uCa was decreased in both GHS and Sprague-Dawley rats [36] . However, even on LCD, uCa from GHS rats was higher than from Sprague-Dawley rats, and higher than the total dietary Ca, indicating that bone is an important contributor to increased uCa in GHS rats. However, from this study, it is not clear whether the contribution from bone is due to a primary increase in bone resorption or a decrease in renal tubular Ca reabsorption leading to enhanced bone resorption, or a combination of these factors.
To determine the contribution of bone to the hypercalciuria, we cultured calvariae from the GHS rats and found greater Ca resorption from bone in response to graded doses of 1,25D than calvariae from Sprague-Dawley rats [3] , consistent with a primary increase in bone resorption in the GHS rats. The increased levels of vitamin D receptors (VDRs) found in GHS bone cells [37, 53, 61] were apparently inducing increased bone resorption. To further assess the contribution of bone resorption to hypercalciuria, GHS or Sprague-Dawley rats were fed LCD and injected with the bisphosphonate alendronate to inhibit bone resorption [52] . Although uCa from GHS was greater than that from Sprague-Dawley with LCD alone, alendronate eliminated the difference and restored a positive Ca balance.
However, increased intestinal Ca absorption and bone resorption do not exclude a contribution to the hypercalciuria from decreased renal tubular Ca reabsorption. Using parathyroidectomized GHS and Sprague-Dawley rats, we found that at a similar filtered Ca load there was far less renal tubular reabsorption in GHS rats compared with controls [39] . Diuretic studies strongly suggested that there was decreased tubular Ca reabsorption in the thick ascending limb of Henle's loop; however, that study could not exclude other sites of disordered Ca
KEY POINTS
GHS rats provide a useful model of human idiopathic hypercalciuria.
Similar to many stone-forming patients, GHS rats display decreased BMD.
This reduction in BMD can be ameliorated in GHS by the treatment of the hypercalciuria with thiazide diuretics.
The hypercalciuria in GHS seems to be a consequence of increased vitamin D receptor levels in tissues important in calcium transport (intestine, kidney and bone). 
GHS generation

CONTRIBUTION OF INCREASED LEVELS OF VITAMIN D RECEPTORS TO HYPERCALCIURIA
GHS rats have increased intestinal Ca absorption [62] , increased bone Ca resorption [37] and reduced renal tubular Ca reabsorption [39] compared with their parental strain, Sprague-Dawley rats. In each of these tissues, GHS rats have increased numbers of VDRs, while circulating levels of 1,25D are generally normal [36, 38, 45, 46, 53] . Increased VDRs have been found in one study of human IH [61] but not in others [63, 64] . The increased number of VDRs coupled to a normal level of 1,25D suggests that in GHS rats, the VDR is undersaturated with 1,25D. Indeed, when GHS rats were fed a low Ca diet, their intestinal Ca absorption increased to a greater extent than Sprague-Dawley, even though their s1,25D did not increase as much [32] . Thus, the increased VDRs in GHS led to a greater increase in intestinal Ca absorption even with a smaller increase in circulating 1,25D compared with Sprague-Dawley. With more VDRs in GHS, addition of exogenous 1,25D should increase hypercalciuria in GHS to a greater extent than in Sprague-Dawley rats. To test this hypothesis, GHS and Sprague-Dawley rats were fed a diet containing ample Ca and injected with either 1,25D or vehicle for 16 days [57] . With 1,25D, uCa in Sprague-Dawley increased by 22.4 AE 1.5 mg/ 24 h, whereas in GHS uCa increased by 29.8 AE 1.8 (P ¼ 0.003, Fig. 2 ) [57] . These data demonstrate that the increased number of VDRs in GHS as compared with Sprague-Dawley leads to a greater physiological effect (increase in uCa), indicating that the additional VDRs in GHS rats are biologically active. We would expect 1,25D-induced increased intestinal Ca absorption [32] and 1,25D-induced increased bone resorption [37] each to contribute to the increased uCa observed in GHS with 1,25D.
In IH patients [65] and GHS rats [36] , decreased dietary Ca leads to decreased uCa. To study the effects of 1,25D on kidney and bone Ca handling, we utilized a low Ca diet to effectively eliminate the contribution of increased intestinal absorption on the 1,25D-induced increase in uCa in GHS. GHS and Sprague-Dawley rats were fed a low-Ca (0.02%) diet (LCD) and injected with 1,25D [58] . Any increase in uCa would arise from increased bone resorption, decreased renal tubular reabsorption, or a combination of these two factors. With 1,25D, uCa in Sprague-Dawley increased by 8.1 AE 1.0 mg/24 h and increased to an even greater extent in GHS by 16.8 AE 0.8 mg/24 h (P < 0.001). In GHS rats on LCD with or without 1,25D, uCa far exceeded daily Ca intake (no more than 2.6 mg/day), indicating that the biological activity of the increased VDRs in bone cells and renal tubules must be a major contributor to the increased uCa in GHS rats. Thus, on a very low Ca diet, the decrease in net intestinal Ca absorption (in spite of an increase in percentage Ca absorption) is greater than the decrease in uCa, leading to an exacerbation of the net negative Ca balance.
The increased biological activity of the VDR in GHS intestine and bone leads to a greater influx of Ca into the systemic circulation. Basal renal tubular Ca reabsorption in GHS rats is decreased relative to Sprague-Dawley [39] , but the effects of 1,25D on renal tubular Ca reabsorption are not clear. To determine if 1,25D alters RNA expression of components of renal tubular Ca reabsorption (reviewed in [66] [67] [68] ) associated with hypercalciuria while rats were fed a normal Ca diet, we measured kidney RNA expression of transient receptor potential vanilloid (TRPV)5 and calbindin D 28K , which were increased similarly in Sprague-Dawley þ 1,25D and GHS þ 1,25D. The Na þ /Ca 2þ exchanger (NCX1) was increased in GHS þ 1,25D. Klotho, which activates TRPV5, was decreased in Sprague-Dawley þ1,25D and GHS þ 1,25D. TRPV6 was increased in Sprague-Dawley þ 1,25D and increased further in GHS þ 1,25D. Claudin 14, 16 and 19, Na/K/2Cl transporter (NKCC2) and secretory K channel (ROMK) did not differ between Sprague-Dawley þ 1,25D and GHS þ 1,25D. Although the changes in RNA abundance are more consistent with increased Ca reabsorption, the observed increase in uCa, which must come from increased intestinal absorption or increased bone resorption, or both of these factors, must exceed any effect of 1,25D on TRPV6 or NCX1-mediated renal Ca reabsorption. We next determined if there was also a 1,25D-mediated decrease in RNA expression of the components of renal Ca transport while rats were fed LCD. 1,25D administration resulted in a suppression of klotho, an activator of the renal Ca reabsorption channel TRPV5, in both Sprague-Dawley and GHS rats. This fall in klotho would be expected to decrease tubular reabsorption of the Ca released from bone by 1,25D-induced resorption. Further studies of actual transport activity are necessary to directly address the effects of 1,25D on tubular Ca transport in GHS rats.
To eliminate the component of bone resorption in 1,25D-stimulated hypercalciuria in GHS rats, we utilized the bisphosphonate alendronate (alen) [59 & ]. Sprague-Dawley and GHS rats were fed LCD and half were injected daily with 1,25D. After 8 days, all were also injected with alen until euthanasia at day 16. At 8 days, 1,25D increased uCa in Sprague-Dawley and, to an even greater extent, in GHS rats ( Fig. 3) 
]. At 16 days, alen eliminated the 1,25Dinduced increase in uCa in Sprague-Dawley. However, in GHS rats, alen decreased, but did not eliminate, the 1,25D-induced hypercalciuria, suggesting that even a large dose of alen cannot completely prevent the 1,25D-induced bone resorption in GHS.
This partial resistance to alen may be due to the increased VDR in GHS tissues. Although decreased renal tubular Ca reabsorption would contribute to the hypercalciuria in GHS rats fed LCD and given alen, there were no consistent differences in mRNA expression of renal transcellular or paracellular Ca transporters between GHS and Sprague-Dawley [59 
HOW DOES THE HYPERCALCIURIA OF GENETIC HYPERCALCIURIC STONE-FORMING RATS AFFECT BONE QUALITY?
In humans, kidney stone patients often have decreased BMD [15, 18, 69, 70] , and our studies indicate that bone is an important contributor to the hypercalciuria in GHS rats. The hypercalciuriainduced loss of Ca from existing bone would be expected to decrease bone quality in GHS rats. GHS and control Sprague-Dawley rats were fed a constant amount of either a low Ca or a high Ca (HCD) diet for 6 weeks [35] . Urine Ca was greater in the GHS rats on either diet. GHS rats fed HCD had reduced cortical (humerus) and trabecular (L1-L5 vertebrae) BMD as compared with Sprague-Dawley ( Fig. 4) [35] . GHS rats fed HCD had a decrease in trabecular volume and thickness, whereas LCD led to an approximately 20-fold increase in both osteoid surface and volume. GHS rats fed HCD had no change in vertebral strength (failure stress), ductibility (failure strain), stiffness (modulus) or toughness, whereas in the humerus, there was reduced ductibility and toughness and an increase in modulus, indicating that the defect in mechanical properties is mainly manifested in cortical, rather than trabecular, bone. GHS rat cortical bone is more mineralized than trabecular bone and LCD led to a decrease in the mineralization profile. Thus, the GHS rats, fed an ample Ca diet, have reduced BMD with reduced trabecular volume, mineralized volume and thickness, and their bones are more brittle and fracture prone, indicating that GHS rats have an intrinsic disorder of bone that is not secondary to any reduction in dietary Ca.
As we have shown that 1,25D induces a greater increase in uCa in GHS than Sprague-Dawley rats, we hypothesized that 1,25D would exacerbate the bone defects seen in GHS rats. We fed both GHS and Sprague-Dawley rats an ample Ca diet and injected either low (LD) or high dose (HD) 1,25D or vehicle (veh) daily for 16 days [60 & ]. Femoral areal bone mineral density (aBMD, by DEXA) was decreased in GHS þ LD and GHS þ HD relative to GHS þ veh, while there was no effect on Sprague-Dawley. Vertebral aBMD was lower in GHS compared with Sprague-Dawley and further decreased in GHS þ HD. Both femoral and L6 vertebral volumetric BMD (by micro-CT) were lower in GHS and further reduced by HD. Histomorphometry indicated a decreased osteoclast number in GHS þ HD compared with GHS þ veh or SD þ HD. In tibiae, GHS þ HD trabecular thickness and number increased, with a 12-fold increase in osteoid volume but only a three-fold increase in bone volume ( Fig. 5) [60 & ]. Bone formation rate was decreased in GHS þ HD relative to GHS þ veh, confirming the mineralization defect. The loss of BMD and the mineralization defect in GHS rats contribute to increased hypercalciuria; if these effects persist, they would result in decreased bone strength, making the bones from GHS rats more fracture-prone. The deleterious effects of exogenous 1,25D on bone quality in GHS rats indicate that the increased amount of VDR in these animals plays an important role in determining their bone health.
To examine the mechanism of 1,25D activity on bone in GHS rats, we examined VDR effects on bone morphogenetic protein 2 (BMP2) [71] . Both 1,25D and BMP2 are critical for normal maintenance of bone metabolism and bone formation, respectively. The complex nature of bone cell regulation suggests a potential interaction of these two important regulators in GHS rats. BMP2 expression is suppressed by the VDR-1,25D complex in bone marrow stromal cells (BMSCs) from GHS and Sprague-Dawley rats and in the UMR-106 rat osteosarcoma cell line (Fig. 6) [71] . Chromatin immunoprecipitation (ChIP) assays identified VDR binding only to one of several potential binding sites within the BMP2 promoter regions, an inhibitory region that also mediates suppressor reporter gene activity. Genes can be epigenetically regulated by modification of DNA or histones, producing marks that modulate protein interactions [72] . The down-regulation of BMP2 by 1,25D was studied in vitro in BMSCs and UMR-106 cells using the DNA methyltransferase inhibitor 5-aza-2'-deoxycytidine (DAC) and the histone deacetylase inhibitor trichostatin A (TSA). Both DAC and TSA activate BMP2 expression in combination with 1,25D. Bisulfite DNA pyrosequencing reveals that 1,25D completely hypermethylates a single CpG site in the same BMP2 promoter region as identified by the ChIP and reporter gene assays. ChIP assays also show that 1,25D can increase the repressive histone H3K9me2 mark and reduce the acetylation of histone H3 at the same BMP2 promoter region. Taken together, our results indicate that 1,25D binding to VDR downregulates BMP2 gene expression in BMSCs and osteoblast-like UMR-106 cells by binding to the BMP2 promoter region via DNA methylation and histone modification. These results suggest that exogenously supplied BMP2 might enhance bone quality in GHS rats and perhaps in IH patients. 
DO STRATEGIES DIRECTED TOWARD REDUCING RECURRENT STONE FORMATION AMELIORATE THE DECREASED BONE QUALITY IN GENETIC HYPERCALCIURIC STONE-FORMING RATS?
Clinically, thiazide diuretics reduce uCa and prevent recurrent stone formation in human stone-forming patients [73] [74] [75] [76] ; however, whether they also lead to an improvement in bone quality is not clear. We used GHS rats to test the hypothesis that the thiazide diuretic chlorthalidone (CTD) would have a favorable effect on bone density and quality [40] . GHS rats were fed a 1.2% Ca diet, and half were also fed CTD. As anticipated, rats fed CTD had a marked reduction in uCa. An increase in trabecular mineralization was observed with CTD compared with controls. CTD also improved the architecture of Genetic hypercalciuric stone-forming rats Frick et al.
trabecular bone. Using micro-CT, trabecular bone volume, trabecular thickness and trabecular number were increased with CTD. A significant increase in trabecular thickness with CTD was confirmed by static histomorphometry. CTD also improved the connectivity of trabecular bone. Significant improvements in vertebral strength and stiffness were measured by vertebral compression. Conversely, a slight loss of bending strength was detected in the femoral diaphysis with CTD. Thus, results obtained in GHS rats suggest that CTD can favorably influence vertebral fracture risk. CTD did not alter formation parameters, suggesting that the improved vertebral bone strength was due to decreased bone resorption and retention of bone structure, rather than enhanced bone formation.
CONCLUSION
In GHS rats, the hypercalciuria results from a systemic dysregulation of Ca transport affecting the major Ca transporting organs: intestine [38] , bone [37] and kidney [39] . In the GHS rats, an increased level of VDR has been found in each of these organs and we have found that 1,25D leads to greater alterations in Ca transport at each of these sites than in Sprague-Dawley. Thus, in GHS rats, the hypercalciuria appears to be directly related to excessive VDR activity. A similar role for VDR activity appears important in human hypercalciuria. Lemann [77] fed normal men vitamin D and replicated hypercalciuria and negative Ca balance. If human IH can also be shown to be due to increased VDR leading to an increased effect of circulating 1,25D, then strategies can be devised to reduce the hypercalciuria and improve bone quality and perhaps ultimately eliminate recurrent Ca stone disease. 6 . VDR levels and BMP2 expression in GHS and SD rats. Nuclear proteins were isolated from BMSCs and tissues of SD and GHS rats and were subjected to Western blot using anti-VDR. Representative data are shown in (a). Expression of BMP2 in BMSCs, kidney and intestine tissues from GHS rats decrease relative to SD rats (b, c, d). ( Ã P < 0.05; ÃÃ P < 0.01). BMP2, bone morphogenetic protein 2; BMSCs, bone marrow stromal cells; GHS, genetic hypercalciuric stone-forming; SD, Sprague-Dawley; VDR, vitamin D receptor. From [71] .
